Leukocytapheresis in a girl with severe ulcerative colitis refractory to corticosteroids, infliximab, and cyclosporine A
✍ Scribed by Katalin Dittrich; Markus Richter; Wolfgang Rascher; Henrik Köhler
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 461 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background: Cyclosporine (CsA) or infliximab (IFX) are used as rescue therapies in steroid-refractory, severe attacks of ulcerative colitis (UC). There are no data comparing the efficacy of these two alternatives. Methods: Outcome of rescue therapy was retrospectively studied in two cohorts of pati
## Background: Recent reports suggest that the preoperative use of infliximab (ifx) increases postoperative infectious complications in patients with ulcerative colitis (uc). therefore, we determined the impact of ifx on postoperative infectious complications. ## Methods: A consecutive group of 1
Background: Cyclosporine A (CsA) is inconstantly effective in inducing remission in acute attacks of ulcerative colitis (UC) not responding to steroids. This study aimed to establish whether multidrug resistance gene (MDR)1 polymorphisms would be associated with CsA failure. ## Patients and Methods